XML 43 R32.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2017
Segment Reporting [Abstract] |
Sales of Company's products | Sales of the Company’s products were as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2017 |  | 2016 |  | 2017 |  | 2016
Primary Care and Women’s Health |  |  |  |  |  |  |
Cardiovascular |  |  |  |  |  |  |
Zetia | $ | 320 |  |  | $ | 671 |  |  | $ | 1,021 |  |  | $ | 1,985 |
Vytorin | 142 |  |  | 273 |  |  | 565 |  |  | 843 |
Atozet | 59 |  |  | 39 |  |  | 171 |  |  | 96 |
Adempas | 70 |  |  | 48 |  |  | 221 |  |  | 120 |
Diabetes |  |  |  |  |  |  |
Januvia | 1,012 |  |  | 1,006 |  |  | 2,799 |  |  | 2,976 |
Janumet | 513 |  |  | 548 |  |  | 1,572 |  |  | 1,624 |
General Medicine and Women’s Health |  |  |  |  |  |  |
NuvaRing | 214 |  |  | 195 |  |  | 573 |  |  | 571 |
Implanon/Nexplanon | 155 |  |  | 148 |  |  | 503 |  |  | 446 |
Follistim AQ | 72 |  |  | 101 |  |  | 232 |  |  | 268 |
Hospital and Specialty |  |  |  |  |  |  |
Hepatitis |  |  |  |  |  |  |
Zepatier | 468 |  |  | 164 |  |  | 1,363 |  |  | 326 |
HIV |  |  |  |  |  |  |
Isentress/Isentress HD | 310 |  |  | 372 |  |  | 896 |  |  | 1,050 |
Hospital Acute Care |  |  |  |  |  |  |
Bridion | 185 |  |  | 139 |  |  | 495 |  |  | 343 |
Noxafil | 162 |  |  | 147 |  |  | 458 |  |  | 434 |
Invanz | 159 |  |  | 152 |  |  | 445 |  |  | 409 |
Cancidas | 94 |  |  | 142 |  |  | 327 |  |  | 406 |
Cubicin | 91 |  |  | 320 |  |  | 290 |  |  | 969 |
Primaxin | 73 |  |  | 77 |  |  | 206 |  |  | 231 |
Immunology |  |  |  |  |  |  |
Remicade | 214 |  |  | 311 |  |  | 651 |  |  | 999 |
Simponi | 219 |  |  | 193 |  |  | 602 |  |  | 581 |
Oncology |  |  |  |  |  |  |
Keytruda | 1,047 |  |  | 356 |  |  | 2,512 |  |  | 919 |
Emend | 137 |  |  | 137 |  |  | 413 |  |  | 405 |
Temodar | 68 |  |  | 78 |  |  | 198 |  |  | 216 |
Diversified Brands |  |  |  |  |  |  |
Respiratory |  |  |  |  |  |  |
Singulair | 161 |  |  | 239 |  |  | 550 |  |  | 705 |
Nasonex | 42 |  |  | 94 |  |  | 266 |  |  | 425 |
Dulera | 59 |  |  | 97 |  |  | 210 |  |  | 331 |
Other |  |  |  |  |  |  |
Cozaar/Hyzaar | 128 |  |  | 131 |  |  | 360 |  |  | 389 |
Arcoxia | 80 |  |  | 114 |  |  | 272 |  |  | 342 |
Fosamax | 53 |  |  | 68 |  |  | 180 |  |  | 217 |
Vaccines (1) |  |  |  |  |  |  |
Gardasil/Gardasil 9 | 675 |  |  | 860 |  |  | 1,675 |  |  | 1,631 |
ProQuad/M-M-R II/Varivax | 519 |  |  | 496 |  |  | 1,273 |  |  | 1,236 |
Pneumovax 23 | 229 |  |  | 175 |  |  | 558 |  |  | 403 |
Zostavax | 234 |  |  | 190 |  |  | 547 |  |  | 464 |
RotaTeq | 179 |  |  | 171 |  |  | 525 |  |  | 489 |
Other pharmaceutical (2) | 1,013 |  |  | 1,191 |  |  | 3,172 |  |  | 3,398 |
Total Pharmaceutical segment sales | 9,156 |  |  | 9,443 |  |  | 26,101 |  |  | 26,247 |
Other segment sales (3) | 1,100 |  |  | 977 |  |  | 3,188 |  |  | 2,862 |
Total segment sales | 10,256 |  |  | 10,420 |  |  | 29,289 |  |  | 29,109 |
Other (4) | 69 |  |  | 116 |  |  | 400 |  |  | 583 |
| $ | 10,325 |  |  | $ | 10,536 |  |  | $ | 29,689 |  |  | $ | 29,692 |
(1) | On December 31, 2016, Merck and Sanofi terminated their equally-owned joint venture, SPMSD, which marketed vaccines in most major European markets. Accordingly, vaccine sales in 2017 include sales in the European markets that were previously part of SPMSD. Amounts for 2016 do not include sales of vaccines sold through SPMSD, the results of which are reflected in equity income from affiliates which is included in Other (income) expense, net. Amounts for 2016 do, however, include supply sales to SPMSD.
(2) | Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(3) | Represents the non-reportable segments of Animal Health, Healthcare Services and Alliances.
(4) | Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. Other in the first nine months of 2017 and 2016 also includes $60 million and $75 million, respectively, related to the sale of the marketing rights to certain products.
Reconciliation of segment profits to income before taxes | A reconciliation of segment profits to Income before taxes is as follows:
| Three Months Ended September 30, |  | Nine Months Ended September 30,
($ in millions) | 2017 |  | 2016 |  | 2017 |  | 2016
Segment profits: |  |  |  |  |  |  |
Pharmaceutical segment | $ | 5,929 |  |  | $ | 6,162 |  |  | $ | 16,722 |  |  | $ | 16,698 |
Other segments | 482 |  |  | 389 |  |  | 1,442 |  |  | 1,129 |
Total segment profits | 6,411 |  |  | 6,551 |  |  | 18,164 |  |  | 17,827 |
Other profits | (78 | ) |  | 21 |  |  | 107 |  |  | 341 |
Unallocated: |  |  |  |  |  |  |
Interest income | 90 |  |  | 87 |  |  | 284 |  |  | 244 |
Interest expense | (189 | ) |  | (170 | ) |  | (564 | ) |  | (513 | )
Equity income from affiliates | 23 |  |  | (27 | ) |  | 16 |  |  | (13 | )
Depreciation and amortization | (334 | ) |  | (365 | ) |  | (1,036 | ) |  | (1,228 | )
Research and development | (1,829 | ) |  | (1,444 | ) |  | (4,955 | ) |  | (4,651 | )
Aggregate charge related to the formation of an oncology collaboration with AstraZeneca | (2,350 | ) |  | — |  |  | (2,350 | ) |  | — |
Amortization of purchase accounting adjustments | (765 | ) |  | (772 | ) |  | (2,322 | ) |  | (2,933 | )
Restructuring costs | (153 | ) |  | (161 | ) |  | (470 | ) |  | (386 | )
Gain on sale of certain migraine clinical development programs | — |  |  | 40 |  |  | — |  |  | 40 |
Other unallocated, net | (626 | ) |  | (873 | ) |  | (2,232 | ) |  | (2,713 | )
| $ | 200 |  |  | $ | 2,887 |  |  | $ | 4,642 |  |  | $ | 6,015 |

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599 + Details
Name: | us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration